Objectives: To compare virological effectiveness in patients who continued on a virologically successful first-line boosted protease inhibitor (PI)-containing combination antiretroviral therapy (cART) regimen or who switched to a PI-free cART including efavirenz, nevirapine or abacavir.
Introduction
Potent protease inhibitor (PI)-containing combination antiretroviral therapy (cART) drastically reduces the morbidity and mortality associated with HIV infection, 1 while reducing the viral load (VL) below the detection limit and increasing the CD4 cell count. 2, 3 Such regimens sometimes need to be replaced, however, mainly because of PI toxicity (hepatic or gastrointestinal disorders, lipodystrophy, hyperlipidaemia, diabetes mellitus and an excess of cardiovascular events independent of metabolic changes), drug/drug interactions or for simplification. 4 -6 Although some non-nucleoside reverse transcriptase inhibitors (NNRTIs) have been reported to affect cholesterol, triglyceride and blood glucose levels, 4, 7 NNRTIs are not associated with an independent cardiovascular risk, 5 nor was cumulative exposure for .1 year or past exposure to abacavir. 8 -12 Clinical trials show that efavirenz and nevirapine, when combined with two nucleoside reverse transcriptase inhibitors (NRTIs), have similar virological efficacy in antiretroviral-naive patients. 13, 14 This is despite the fact that non-inferiority was not demonstrated in these studies when considering the primary composite endpoint (i.e. disease progression, virological failure and therapy change) efficacy outcome. 13, 14 Triple NRTI therapy including abacavir is less potent. 15, 16 Simplification of PI-containing regimens is virologically safe, at least in patients who do not harbour archived resistance mutations. 17 However, randomized trials have limited power to detect differences in the risk of virological rebound between different switch strategies after a first-line PI-containing cART (PI-cART) regimen. Cohort studies suggest that switching to a nevirapine-or abacavircontaining regimen from a virologically successful first-line PI-cART regimen is associated with more virological failures than switching to an efavirenz-containing regimen, 18, 19 but none of these studies compared switch regimens with ongoing first-line PI-cART.
Here, to compare the efficacy of PI-free switch regimens with that of continued first-line PI-cART in patients with no acquired resistance mutations, we compared virological outcomes among patients enrolled in the French Hospital Database on HIV (FHDH) who had sustained undetectable VL on a first PI-cART regimen and who either continued the same treatment or switched to a PI-free regimen. We also compared virological outcomes according to whether the switch regimen contained efavirenz, nevirapine or abacavir.
Methods

Patients
The FHDH is a large prospective cohort study of HIV-infected patients aged ≥15 years and is managed in 68 French university hospitals. The only enrolment criteria are documented HIV-1 or HIV-2 infection and written informed consent. Trained research assistants use the French Ministry of Health DMI2 software to collect clinical and biological data prospectively at inclusion and at each visit or hospital admission for an HIV-related clinical event or a new treatment prescription, or at least every 6 months, on standardized forms.
For this study, we selected 9208 antiretroviral-naive HIV-1-infected patients starting a first-line PI-cART regimen (at least three antiretroviral drugs with at least two NRTIs plus a ritonavir-boosted PI) between 1 January 1998 and 31 December 2008, and who had at least two subsequent follow-up visits. Of these, 1174 patients were excluded because their regimen included abacavir or an NNRTI. We subsequently selected 6011 patients whose plasma VL (pVL) remained undetectable (,500 copies/mL) for ≥6 months on their first-line regimen. The date of virological failure was the date of the first of two consecutive pVL values ≥500 copies/mL recorded ≥1 month apart. The cut-off date for database analysis was 31 December 2008. Exposed patients were patients who switched from their first virologically successful PI-containing regimen to cART composed of two NRTIs plus efavirenz, nevirapine or abacavir. The NRTI backbone could also be modified at the switch. We selected 439 patients with no virological failure between their first undetectable pVL on cART and the switch date.
Each exposed patient was matched with three unexposed patients who were randomly chosen with incident density sampling among the 3173 patients who had not switched to another cART regimen and who had the same duration (+6 months) of pVL undetectability as the exposed patients on their first-line PI-cART regimen. 20 To approach the design of a randomized trial, unexposed patients were also matched with exposed patients on the basis of sex, age (+5 years), CD4 cell count (,350 and ≥350 cells/mm 3 ) and VL (,4 log 10 , 4-5 log 10 and ≥5 log 10 copies/mL) at the date of PI-cART initiation and the date of cART initiation (+6 months). 21 The index date was the date of the switch for exposed patients and the matching date for unexposed patients, i.e. the date at which the length of virological rebound-free follow-up on first-line cART was the same as in the matched exposed patient prior to the switch. A total of 1261 unexposed patients were selected.
Statistical analysis
Time to first subsequent virological failure was analysed by means of Kaplan-Meier life-table methods and Cox proportional hazard models. First, unexposed (PI-cART) and exposed (switch-cART) patients were compared, regardless of the drugs in the switch regimen. We then compared four groups of patients: (i) those who kept their first PI-cART; and those who switched to regimens containing (ii) efavirenz (efavirenz-cART), (iii) nevirapine (nevirapine-cART) or (iv) abacavir (abacavir-cART). Follow-up data were censored at the date of any subsequent change in cART.
Thus, follow-up ended at the date of virological failure, the last follow-up visit, death or 31 December 2008, whichever occurred first.
Potential confounding variables considered in the analyses were: the HIV transmission group; the NRTI backbone and PI in the first-line PI-cART regimen; and, at the index date, AIDS status, the CD4 cell count, the NRTI backbone, the calendar period, time since enrolment in the database, time since PI-cART initiation, and time between undetectability and the switch. Each variable associated with virological failure in the univariate model (P, 0.20) was included in a multivariable model designed to evaluate the impact of the switch, and then the precise switch regimen, on the risk of virological failure, after adjustment for other risk factors. Each model was stratified by the matched groups (exposed/matched unexposed patients). The SAS statistical package version 9.1 was used for all analyses (SAS Institute, Cary, NC, USA).
Results
Matching ensured that the 439 switch patients and the 1261 non-switch patients were similar with regard to sex (68% male), age (both medians 37 years), the CD4 count stratum (82% ,350 cells/mm 3 ), VL at cART initiation (both medians 5.07 log 10 copies/mL) and the calendar period of cART initiation (1998 -2003 in 67% of cases; Table 1 ). However, the median absolute CD4 counts were slightly different, with 192 cells/mm 3 in switch patients and 167 cells/mm 3 in non-switch patients (P,0.01, Wilcoxon rank sum test).
In this population of 1700 patients (439 switch patients plus 1261 non-switch patients), the ritonavir-boosted PI included in the first PI-cART regimen was lopinavir in 1048 cases (61.7%), indinavir in 391 (23.0%), saquinavir in 118 (6.9%), fosamprenavir in 71 (4.2%), atazanavir in 69 (4.1%) and darunavir in 3 (0.1%). The NRTI backbone was mainly zidovudine/lamivudine (1131 patients, 66.5%).
At the index date, 196 patients (44.7% of the switchers) switched to efavirenz-cART, 123 (28.0%) to nevirapine-cART and 120 (27.3%) to abacavir-cART ( Date of switch for patients switching to PI-free cART (efavirenz-, nevirapine-or abacavir-cART) and matching date for non-switch patients (i.e. the date corresponding to the same virological rebound-free follow-up on first-line cART as in the matched exposed patient before the switch).
Switching from PI to EFV, NVP or ABC (293 -596) in patients who switched to efavirenz-, nevirapine-or abacavir-containing cART, respectively (P,0.01). Median follow-up after the index date was 35 months for the whole population, 34 months (IQR 11 -54) for the switchers and 36 months (IQR 15-56) for the non-switchers.
A virological failure occurred in 153 patients (40 exposed and 113 unexposed) during a total follow-up of 5215.16 person-years. The Kaplan-Meier 12 month probability of virological rebound was 5.7% (95% CI, 3.8%-8.6%) for patients who switched to PI-free cART and 3.7% (95% CI, 2.8%-5.0%) for patients who did not switch. There was no difference in the rate of virological rebound between these two groups of patients at 60 months (P¼0.61, log-rank test). Among the 439 patients who switched to PI-free cART, the 12 month probability of virological rebound was 3.9% (95% CI, 1.8%-8.4%) in those who switched to efavirenz-cART, 7.2% (95% CI, 3.7%-13.9%) in those who switched to nevirapine-cART and 9.0% (95% CI, 4.9%-16.1%) in those who switched to abacavir-cART; the differences between these subgroups were not significant (P¼0.26; Figure 1 ).
After adjustment for the PI included in the first cART regimen, as well as the CD4 count and AIDS status at the date of the switch, switching was not associated with a higher risk of virological failure [crude hazard ratio (HR), 1.20; 95% CI, 0.81 -1.77; adjusted HR (aHR), 1.19; 95% CI, 0.80 -1.76, compared with non-switch]. However, after adjustment, switching to abacavir-containing cART was associated with a roughly 2-fold increase in the risk of virological failure (aHR for abacavir-cART versus non-switch, 1.99; 95% CI, 1.05-3.79), while switching to efavirenz-or nevirapine-containing regimens . Kaplan-Meier curves for the probability of virological rebound-free survival after the index date, comparing patients who did not switch and patients who switched to PI-free cART, whatever the switch regimen (upper graph) and according to the switch regimen (lower graph ) and AIDS diagnosis before the index date (aHR, 1.55; 95% CI, 0.94 -2.55) were associated with a higher risk of virological rebound (Table 2 ).
Discussion
This study shows that patients switching from a virologically effective first-line boosted PI-cART regimen to a cART regimen containing efavirenz or nevirapine have similar virological outcomes to patients who continue on the first-line regimen, whereas patients switching to a regimen containing abacavir have an increased risk of virological failure.
In cohort studies, differences in virological outcome associated with different regimens do not necessarily reflect differences in efficacy, as bias due to residual confounding factors cannot be excluded despite adjustments for factors known to be associated with outcome. 22, 23 However, by matching patients who switched and patients who did not switch for factors known to influence virological outcome, such as age, sex, the CD4 count and VL at cART initiation, the duration of VL undetectability, and the date of first cART, we tried to mimic the design of a randomized study. We also took into account residual confounding factors that might have influenced the decision to prescribe a specific switch regimen, such as the drugs included in the initial cART regimen, and the CD4 count and AIDS status at the index date. In addition, we adopted an intention-to-treat approach, as used in randomized studies. Sensitivity analyses in which follow-up was censored at the date of any further change in the cART in the switch and non-switch populations gave similar results, as did analyses focusing separately on the first year after the index date or the subsequent follow-up period (data not shown). Analysis also gave similar results when the date of virological failure after the index date was defined as the date of the first of two consecutive pVL values ≥500 copies/mL, whatever the delay between the two detectable VL (data not shown). The FHDH, owing to its very large size and extensive follow-up, allows rare events such as virological rebound to be studied in selected patients treated with potent regimens and gives the opportunity to assess clinical practice in everyday life.
Although clinical trials of treatment simplification in patients receiving PI-cART have given reassuring results, 17 outcomes tend to be discordant when the third drug included in the regimen (efavirenz, nevirapine or abacavir) is taken into account. 17, 24, 25 Abacavir-containing regimens are frequently compromised by cross-resistance between abacavir and other NRTIs. More than 50% of the patients included in such trials had previously received single-or dual-NRTI therapy, and ≥90% of them received an unboosted PI, facilitating the acquisition of archived resistance mutations. 17, 24 We found no difference in the virological failure rate between patients who switched to PI-free cART and patients who remained on their first-line PI-cART regimen, whereas another cohort study showed a lower virological failure rate in patients switching to efavirenz from a regimen including indinavir, nelfinavir or ritonavir. 26 However, our study included patients treated with newer, more potent and better-tolerated boosted PIs, and Kaplan -Meier curves showed that the risk of virological failure in patients switching to efavirenz was similar to that in non-switchers.
Our data are in keeping with the results of a cohort study showing higher failure rates in patients switching to abacavir than in patients switching to efavirenz, 19 but not with those of cohorts showing higher rates of virological failure with nevirapine than with efavirenz. 18, 19, 23 The efficacy of the switch regimen in these latter studies could have been undermined by the acquisition of resistance mutations to the NRTI background, compromising subsequent virological outcome: most patients had a history of NRTI exposure before their first PI-containing regimen and very few patients received a combination including a boosted PI. Ours is the first cohort study in which only newer boosted PIs were used and in which the patients were antiretroviral naive before the first PI-cART.
In this study, switching to nevirapine was as virologically safe as switching to efavirenz. Nevirapine may be associated with inferior virological outcomes compared with efavirenz in NNRTInaive patients with extensive resistance to other drug classes. 27, 28 In addition to being free of acquired resistance mutations before the PI-cART, our patients had not experienced virological failure during their first-line cART regimen (median 11 months), probably reflecting better initial adherence than in the overall database population. Differences in the intrinsic virological efficacy of nevirapine and efavirenz may be less pronounced in patients with fully susceptible viruses and good adherence, as observed in a clinical trial. 13, 29 In a previous study of switch regimens, 19 we found that switching to abacavir rather than to efavirenz was associated with a significantly higher risk of virological failure only in antiretroviral-experienced patients. However, with an HR of 1.29 and a 95% CI of 0.88-1.89, we could not rule out a difference in naive patients too. Here, the aHR for virological failure was 2.43 (95% CI, ) for switch abacavir-cART compared with switch efavirenz-cART. A cohort study showed similar virological outcomes in antiretroviral-naive patients switching from PI-cART to efavirenz-cART or abacavir-cART, but only 38 patients switched to abacavir and only 3 of them experienced virological failure, yielding an aHR for virological failure of 1.56 (95% CI, 0.24 -10.09) compared with efavirenz, again ruling out firm conclusions. 18 Higher CD4 counts at the switch date were associated with a higher risk of virological failure, for reasons that are unclear.
30
CD4 counts at the switch date were different across the three switch groups: they were the highest in the abacavir-cART arm, probably owing to prescribers' knowledge of the differences in the intrinsic virological potency of the drugs and to the need for a well-tolerated switch treatment in these successfully treated patients. Also, patients with higher CD4 counts might have better subjective health and, thus, adhere less strictly than patients with lower counts. Lopinavir was associated with a higher rate of virological failure than other PIs, mainly including indinavir, which is much less well tolerated. It is possible that patients switching from less-well-tolerated treatments, such as those containing boosted indinavir, had better subsequent Switching from PI to EFV, NVP or ABC 1873 JAC Date of switch for patients switching to PI-free cART (efavirenz-, nevirapine-or abacavir-cART) and matching date for non-switch patients (i.e. the date corresponding to the same virological rebound-free follow-up on first-line cART as in the matched exposed patient before the switch).
adherence and, thus, lower rates of virological failure than patients switching from a better-tolerated PI.
In conclusion, patients with a virologically effective first-line cART regimen including a boosted PI can safely switch to an NNRTI-containing regimen with efavirenz or nevirapine, but not with abacavir.
